Patents by Inventor Oliver Keil
Oliver Keil has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230295651Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?-> 3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3? UTR, wherein the 5? UTR is selected from the group consisting of a 5? UTR of a gene coding for MCP-1 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for RPL12s.c. or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for Ang-2 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for HSP70 or a derivative thereof having a nucleotide identity of at least 85%, a 5? UTR of a gene coding for H3.3.Type: ApplicationFiled: August 10, 2022Publication date: September 21, 2023Inventors: Joerg KAUFMANN, Oliver KEIL, Daniel TONDERA
-
Publication number: 20230263819Abstract: The present invention is related to a composition comprising a lipid composition, a tricarboxylic acid and a nucleic acid molecule, wherein the lipid composition comprises a cationic lipid, a neutral lipid and a shielding lipid, wherein a positive charge excess arising from a larger number of positive charges provided by the cationic lipid molecules in the composition compared to the smaller number of negative charges provided by the nucleic acid molecules in the composition is compensated by the charges provided by the tricarboxylic acid; and methods of use of such composition.Type: ApplicationFiled: August 10, 2022Publication date: August 24, 2023Inventors: Volker FEHRING, Jörg KAUFMANN, Oliver KEIL, Daniel TONDERA
-
Publication number: 20210261980Abstract: The present invention is related to a recombinant nucleic acid construct comprising in 5?->3? direction a 5? UTR, a coding region coding for an effector molecule, and a 3?UTR, wherein the 5? UTR is selected from the group comprising a 5? UTR of a gene or a derivative thereof having a nucleotide identity of at least 85%, wherein the gene is selected from the group consisting of MCP-1, RPL12s.c., Ang-2, HSP70, H3.3., Galectin-9, GADD34, EDN1, HSP70m5, E-selectin, ICAM-1, IL-6 and vWF.Type: ApplicationFiled: February 10, 2021Publication date: August 26, 2021Inventors: Klaus GIESE, Oliver KEIL, Jörg KAUFMANN
-
Patent number: 10980860Abstract: The present invention relates to a polymeric prodrug for use in the treatment, prevention and/or diagnosis a disease of the joint and pharmaceutical compositions and medical devices comprising said polymeric prodrugs.Type: GrantFiled: October 8, 2013Date of Patent: April 20, 2021Assignee: Ascendis Pharma A/SInventors: Dirk Vetter, Ulrich Hersel, Kennett Sprogøe, Nora Kaluza, Oliver Keil, Guillaume Maitro, Harald Rau
-
Patent number: 10729778Abstract: Prodrugs or a pharmaceutically acceptable salt thereof which comprise a covalent treprostinil carrier conjugate, as well as their pharmaceutical composition, may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: GrantFiled: January 27, 2017Date of Patent: August 4, 2020Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Publication number: 20190105400Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: ApplicationFiled: January 27, 2017Publication date: April 11, 2019Applicant: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogoe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Publication number: 20190038557Abstract: The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y? is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individuallyType: ApplicationFiled: February 14, 2018Publication date: February 7, 2019Inventors: Oliver KEIL, Jörg KAUFMANN, Volker FEHRING, Ute SCHAEPER
-
Patent number: 9913912Abstract: The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z1—(X0-L0-PG0)y (I), wherein Z1, X0, L0, PG0 and y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.Type: GrantFiled: December 6, 2013Date of Patent: March 13, 2018Assignee: Ascendis Pharma A/SInventors: Harald Rau, Guillaume Maitro, Ulrich Hersel, Oliver Keil, Thomas Wegge
-
Patent number: 9872864Abstract: The present invention relates to sustained release compositions of prostacyclin, as well as uses thereof, in particular for the prevention and/or treatment of pulmonary arterial hypertension.Type: GrantFiled: August 10, 2012Date of Patent: January 23, 2018Assignee: Ascendis Pharma A/SInventors: Kennett Sprogøe, Harald Rau, Ulrich Hersel, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Patent number: 9873337Abstract: In a method for starting a motor vehicle having a first vehicle electrical system, to which a battery of the motor vehicle is assigned, a second vehicle electrical system, to which an electric machine of the motor vehicle is assigned, and a DC/DC converter for connecting the two vehicle electrical systems, for starting, electrical energy from the second vehicle electrical system is converted via the DC/DC converter and transferred into the first vehicle electrical system if an actual value of at least one operating parameter of the battery falls below a setpoint value prior to a starting operation to be carried out.Type: GrantFiled: April 25, 2013Date of Patent: January 23, 2018Assignee: ROBERT BOSCH GMBHInventors: Felix Stoller, Albert Geiger, Oliver Keil, Amalinda Christina Post, Eberhard Schoch, Turgut Karacay, Juergen Motz, Stefan Raeumschuessel, Stefan Harport, Sebastian Walenta
-
Publication number: 20170296469Abstract: The present invention is related to a lipid composition contained in and/or containing a carrier comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is optionally removable from the lipid composition under in vivo conditions, whereby the lipid composition containing carrier has an osmolarity of about 50 to 600 mosmole/kg, preferably about 250-350 mosmole/kg, and more preferably about 280 to 320 mosmole/kg, and/or whereby liposomes formed by the first lipid component and/or one or both of the helper lipid and the shielding compound in the carrier have a particle size of about 20 to 200 nm, preferably about 30 to 100 nm, and more preferably about 40 to 80 nm.Type: ApplicationFiled: March 30, 2017Publication date: October 19, 2017Inventors: JORG KAUFMANN, OLIVER KEIL, ANSGAR SANTEL
-
Publication number: 20170152288Abstract: The present invention relates to the use for affinity purification of an antibody or a fragment of an antibody, of a ligand-substituted matrix comprising a support material and at least one ligand covalently bonded to the support material.Type: ApplicationFiled: February 14, 2017Publication date: June 1, 2017Applicant: NOVALIX DEUTSCHLAND GMBHInventors: Holger BITTERMANN, Klaus BURKERT, Marc ARNOLD, Oliver KEIL, Thomas NEUMANN, Inge OTT, Kristina SCHMIDT, Daniel SCHWIZER, Renate SEKUL
-
Publication number: 20170036990Abstract: The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y? is a pharmaceutically acceptable anion.Type: ApplicationFiled: October 20, 2016Publication date: February 9, 2017Inventors: OLIVER KEIL, JORG KAUFMANN, ANSGAR SANTEL
-
Patent number: 9561287Abstract: The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments, especially for diseases or disorders which can be treated by treprostinil, such as pulmonary arterial hypertension (PAH).Type: GrantFiled: August 10, 2012Date of Patent: February 7, 2017Assignee: Ascendis Pharma A/SInventors: Ulrich Hersel, Harald Rau, Torben Lessmann, Nicola Bisek, Guillaume Maitro, Kennett Sprogøe, Thomas Wegge, Oliver Keil, Joachim Zettler
-
Patent number: 9486538Abstract: The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y? is a pharmaceutically acceptable anion.Type: GrantFiled: August 28, 2015Date of Patent: November 8, 2016Assignee: SILENCE THERAPEUTICS GMBHInventors: Oliver Keil, Jörg Kaufmann, Ansgar Santel
-
Publication number: 20160303047Abstract: The present invention is related to composition comprising a lipid composition, wherein the lipid composition consists of a cationic lipid of formula (I) wherein n is any one of 1, 2, 3, and 4, wherein m is any one of 1, 2 and 3, Y? is an anion, wherein each of R1 and R2 is individually and independently selected from the group consisting of linear C12-C18 alkyl and linear C12-C18 alkenyl; a sterol compound, wherein the sterol compound is selected from the group consisting of cholesterol and stigmasterol; and a PEGylated lipid, wherein the PEGylated lipid comprises a PEG moiety and wherein the PEGylated lipid is selected from the group consisting of a PEGylated phosphoethanolamine of formula (II) wherein each of R3 and R4 is individually and independently linear C13-C17 alkyl, and p is any integer from 15 to 130; a PEGylated ceramide of formula (III) wherein R5 is linear C7-C15 alkyl, and q is any integer from 15 to 130; and a PEGylated diacylglycerol of formula (IV) wherein each of R6 and R7 is individuallyType: ApplicationFiled: December 5, 2014Publication date: October 20, 2016Inventors: OLIVER KEIL, JÖRG KAUFMANN, VOLKER FEHRING, UTE SCHAEPER
-
Patent number: 9387262Abstract: The present invention is related to a lipid composition comprising at least a first lipid component, at least a first helper lipid, and a shielding compound which is removable from the lipid composition under in vivo conditions.Type: GrantFiled: October 6, 2014Date of Patent: July 12, 2016Assignee: SILENCE THERAPEUTICS GMBHInventors: Oliver Keil, Jorg Kaufmann
-
Publication number: 20150359906Abstract: The present invention is related to uses of a composition comprising a pharmaceutically active component and a compound according to formula (I), wherein R1 and R2 are each and independently selected from the group comprising alkyl; n is any integer between 1 and 4; R3 is an acyl selected from the group comprising lysyl, ornithyl, 2,4-diaminobutyryl, histidyl and an acyl moiety according to formula (II), wherein m is any integer from 1 to 3 and Y? is a pharmaceutically acceptable anion.Type: ApplicationFiled: August 28, 2015Publication date: December 17, 2015Inventors: OLIVER KEIL, JÖRG KAUFMANN, ANSGAR SANTEL
-
Publication number: 20150336460Abstract: In a method for starting a motor vehicle having a first vehicle electrical system, to which a battery of the motor vehicle is assigned, a second vehicle electrical system, to which an electric machine of the motor vehicle is assigned, and a DC/DC converter for connecting the two vehicle electrical systems, for starting, electrical energy from the second vehicle electrical system is converted via the DC/DC converter and transferred into the first vehicle electrical system if an actual value of at least one operating parameter of the battery falls below a setpoint value prior to a starting operation to be carried out.Type: ApplicationFiled: April 25, 2013Publication date: November 26, 2015Inventors: Felix Stoller, Albert Geiger, Oliver Keil, Amalinda Christina Post, Eberhard Schoch, Turgut Karacay, Juergen Motz, Stefan Raeumschuessel, Stefan Harport, Sebastian Walenta
-
Publication number: 20150306239Abstract: The present invention relates to carrier-linked prostanoid prodrugs of formula (I) Z1—(X0-L0-PG0)y (I), wherein Z1, X0, L0, PG0 and y have the meaning as indicated in the description and claims; pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising the same. It further relates to their use as medicaments, especially for treating, controlling, delaying or preventing pulmonary arterial hypertension.Type: ApplicationFiled: December 6, 2013Publication date: October 29, 2015Applicant: ASCENDIS PHARMA A/SInventors: Harald Rau, Guillaume Maitro, Ulrich Hersel, Oliver Keil, Thomas Wegge